| Autor: |
Sosman, Jeff A., Kohler, Peter C., Hank, Jacquelyn, Moore, Karen H., Bechhofer, Robin, Storer, Barry, Sondel, Paul M. |
| Zdroj: |
JNCI: Journal of the National Cancer Institute; 01/06/1988, Vol. 80 Issue 1, p60-63, 4p |
| Abstrakt: |
A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 × 10 U/m/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (>50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity. [J Natl Cancer Inst 1988;80:60-63] [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
